Wegovy

Wegovy® (semaglutide) is a prescription GLP-1 receptor agonist used for chronic weight management in certain adults and adolescents with obesity, and in adults with overweight who have at least one weight-related condition. It is used together with a reduced-calorie diet and increased physical activity. In some adults, Wegovy® is also prescribed to reduce the risk of major cardiovascular events when cardiovascular disease is present.

• Contains semaglutide, a GLP-1 receptor agonist
• Used for long-term weight management in eligible patients
• Prescribed alongside diet and lifestyle changes
• May be used in patients with cardiovascular disease for risk reduction

Wegovy® is typically taken as a once-weekly injection under the skin. It can be used at any time of day, with or without food, and is usually taken on the same day each week. Your provider will guide how to start and adjust your dose over time.

• Injected under the skin (abdomen, thigh, or upper arm)
• Taken once weekly on a consistent schedule
• Can be used with or without meals
• Injection sites should be rotated regularly

Wegovy® can cause side effects, most commonly involving the digestive system. These may occur more often when starting treatment or during dose adjustments. It is important to recognize both common reactions and symptoms that require prompt medical attention.

• Common: nausea, diarrhea, vomiting, constipation, abdominal pain
• Other possible: fatigue, headache, dizziness, reflux symptoms
• Risk of low blood sugar when used with certain diabetes medications
• Seek urgent care for severe abdominal pain, which may indicate pancreatitis
• Contact a provider immediately for symptoms such as a lump in the neck or trouble swallowing (possible thyroid tumor risk)

See Important Safety Information

Wegovy® injection can be taken with or without food. Because it is injected under the skin, meals do not affect how it is administered. If you are using the tablet formulation, it must be taken on an empty stomach following specific instructions.

• Injection: no need to coordinate with meals
• Tablet: take in the morning on an empty stomach
• Do not combine tablet with other beverages besides water
• Consistency in timing is important

If you miss a dose, the next step depends on how much time has passed. In some cases, you may still be able to take it, while in others you should skip it and continue as scheduled.

• Take the dose if within the recommended time window
• Skip it if your next scheduled dose is too close
• Do not take two doses at once
• Continue your regular dosing schedule

Yes, the injection day can be changed if needed, but spacing between doses should be maintained to avoid taking doses too close together.

• Ensure sufficient time between injections
• Choose a consistent new weekly day
• Avoid overlapping doses
• Confirm changes with your provider if unsure

Your provider can guide you if your routine changes.

Wegovy® injection is administered under the skin in specific areas. Rotating injection sites helps reduce irritation and supports consistent absorption.

• Common areas: abdomen, thigh, upper arm
• Rotate injection sites weekly
• Avoid irritated or damaged skin
• Use different spots within the same area

Wegovy® may be used with other medications, but combining treatments can increase certain risks. Your provider may adjust your treatment plan accordingly.

• Increased risk of low blood sugar with insulin or sulfonylureas
• Dose adjustments may be needed
• Wegovy® injection should not be mixed with insulin
• Inform your provider about all medications

Always follow your provider’s guidance and report any symptoms.

Certain symptoms may require urgent medical attention. It is important to recognize these early and take action.

• Severe or persistent abdominal pain
• Signs of allergic reaction such as swelling or difficulty breathing
• Ongoing vomiting or diarrhea causing dehydration
• Symptoms like a lump in the neck or trouble swallowing

If you are unsure, contact your provider or seek urgent care.

Yes, you should inform your healthcare providers if you are taking Wegovy® before any procedure involving anesthesia or sedation. This helps them plan safely.

• Inform all providers before surgery
• Follow instructions about pausing treatment if advised
• Timing depends on the procedure and your health status

Proper storage helps maintain the medication’s effectiveness. Planning ahead is especially important when traveling.

• Store according to recommended conditions
• Protect from light where applicable
• Keep in original packaging
• Follow instructions for temporary storage if needed

If traveling, use appropriate storage methods to maintain safe conditions.

Wegovy® should only be used if it has been stored properly and appears normal. Changes in appearance or storage conditions may affect safety.

• Do not use if cloudy or discolored
• Avoid use if particles are visible
• Do not use if stored incorrectly

When in doubt, it is safer to replace the medication.

Wegovy® is not specifically labeled as impairing driving, but certain symptoms may affect your ability to stay alert. It is important to understand how your body responds.

• Be cautious if you feel dizzy or unwell
• Low blood sugar can affect concentration
• Monitor your response after starting or adjusting treatment
• Avoid driving if you are not fully alert

There is no specific instruction in the prescribing information regarding alcohol use. However, alcohol can affect your overall health and treatment plan.

• Alcohol may influence appetite and blood sugar
• Effects vary depending on amount and timing
• Monitor how your body responds

Discuss alcohol use with your provider to ensure it fits your treatment plan.

Getting Wegovy® through US Quick Health starts with an online medical evaluation. A licensed provider reviews your health information and determines whether treatment is appropriate.

• Complete an online consultation or questionnaire
• Provider evaluates your eligibility
• Prescription is issued if appropriate
• Medication is dispensed through a pharmacy
• Follow-up may be recommended

Wegovy® (semaglutide) Prescribing Information - FDA-approved label with indications, dosing, warnings, and safety information. / Source: FDALink: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf / Published: January 2025

**Wegovy® (semaglutide) - complete drug label including contraindications, warnings, and medication guide. / Source: DailyMed (NIH)**Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b / Published: February 2026